{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:44:47Z","timestamp":1791945887448,"version":"4.3.4"},"reference-count":62,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2006,10,31]]},"DOI":"10.2217\/14796694.2.5.591","type":"journal-article","created":{"date-parts":[[2006,10,9]],"date-time":"2006-10-09T11:54:49Z","timestamp":1160394889000},"page":"591-602","source":"Crossref","is-referenced-by-count":33,"title":["Palonosetron: A Second-Generation 5-Hydroxytryptamine Receptor Antagonist"],"prefix":"10.1080","volume":"2","author":[{"given":"Rudolph M","family":"Navari","sequence":"first","affiliation":[{"name":"Professor of Medicine, Assistant Dean &amp; Director, Indiana University School of Medicine \u2013 South Bend, and, Director, Notre Dame Cancer Institute, 1234 Notre Dame Avenue, South Bend, IN46617, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2006,10,9]]},"reference":[{"key":"e_1_3_1_3_1_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.507"},{"key":"e_1_3_1_3_2_1","doi-asserted-by":"publisher","DOI":"10.3816\/SCT.2005.n.011"},{"key":"e_1_3_1_3_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s005200050078"},{"key":"e_1_3_1_3_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.968"},{"key":"e_1_3_1_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11408"},{"key":"e_1_3_1_3_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20230"},{"key":"e_1_3_1_3_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.11.1.137"},{"key":"e_1_3_1_3_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2971"},{"key":"e_1_3_1_3_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.103"},{"key":"e_1_3_1_3_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.116"},{"key":"e_1_3_1_3_11_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006233802863"},{"key":"e_1_3_1_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.08.028"},{"key":"e_1_3_1_3_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0651-0"},{"key":"e_1_3_1_3_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960301)77:5<941::AID-CNCR21>3.0.CO;2-2"},{"key":"e_1_3_1_3_15_1","first-page":"89","article-title":"Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents.","volume":"1","author":"Navari RM","year":"2003","unstructured":"Navari RM : Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents.J.\u00a0Support. Oncol.1, 89\u2013103 (2003).","journal-title":"J.\u00a0Support. Oncol."},{"key":"e_1_3_1_3_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-001-0335-y"},{"key":"e_1_3_1_3_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.9591"},{"key":"e_1_3_1_3_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj078"},{"key":"e_1_3_1_3_19_1","first-page":"470","article-title":"The NCCN antiemesis clinical practice guidelines in oncology.","volume":"2","author":"Ettinger DS","year":"2004","unstructured":"Ettinger DS , BiermanPJ, BradburyBet al.: The NCCN antiemesis clinical practice guidelines in oncology.JNCCN2, 470\u2013490 (2004).","journal-title":"JNCCN"},{"key":"e_1_3_1_3_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.2135"},{"key":"e_1_3_1_3_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.3.596"},{"key":"e_1_3_1_3_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01681959"},{"key":"e_1_3_1_3_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199501053320101"},{"key":"e_1_3_1_3_24_1","first-page":"2937","article-title":"The Italian Group for Anti-emetic Research: Double-blind dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis","volume":"16","year":"1998","unstructured":"The Italian Group for Anti-emetic Research: Double-blind dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. N.\u00a0Engl. J. Med.16, 2937\u20132942 (1998).","journal-title":"N.\u00a0Engl. J. Med."},{"key":"e_1_3_1_3_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/07357909709039729"},{"key":"e_1_3_1_3_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.5.1050"},{"key":"e_1_3_1_3_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.040"},{"key":"e_1_3_1_3_28_1","first-page":"1297","volume-title":"Drugs","author":"Simpson K","year":"2000","unstructured":"Simpson K , SpencerCM, McClellanKJ: Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting.Drugs59, 1297\u20131315 (2000)."},{"key":"e_1_3_1_3_29_1","first-page":"477","article-title":"Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP.","volume":"23","author":"Kimura E","year":"1996","unstructured":"Kimura E , NiimiE, WatanabeAet al.: Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP.Gan To Kagaku Ryoho.23, 477\u2013481 (1996).","journal-title":"Gan To Kagaku Ryoho."},{"key":"e_1_3_1_3_30_1","first-page":"1163","article-title":"Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer.","volume":"26","author":"Taguchi T","year":"1999","unstructured":"Taguchi T , TsukamotoF, WatanabeTet al.: Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer.Gan To Kagaku Ryoho.26, 1163\u20131170 (1999).","journal-title":"Gan To Kagaku Ryoho."},{"key":"e_1_3_1_3_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/07357900009038248"},{"key":"e_1_3_1_3_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2242"},{"key":"e_1_3_1_3_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.5.1242"},{"key":"e_1_3_1_3_34_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C510"},{"key":"e_1_3_1_3_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0700-8"},{"key":"e_1_3_1_3_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.1174"},{"key":"e_1_3_1_3_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.9.2408"},{"key":"e_1_3_1_3_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005253422102"},{"key":"e_1_3_1_3_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.022"},{"key":"e_1_3_1_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70325-9"},{"key":"e_1_3_1_3_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh047"},{"key":"e_1_3_1_3_42_1","unstructured":"Aloxi\u00ae(palonosetron HCl) injection prescribing information. MGI Pharma Inc. Bloomington MN USA (2003)."},{"key":"e_1_3_1_3_43_1","first-page":"6254S","article-title":"Palonosetron, a new 5-HT3 antagonist does not alter antitumor efficacy of various chemotherapeutics in tumor bearing mice","volume":"9","author":"Cantoreggi S","year":"2003","unstructured":"Cantoreggi S , ParisiS, Van LaarEet al.: Palonosetron, a new 5-HT3 antagonist does not alter antitumor efficacy of various chemotherapeutics in tumor bearing mice. Clin. Cancer Res.9, 6254S-6254S (2003) (Abstract).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_1_3_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11817"},{"key":"e_1_3_1_3_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg417"},{"key":"e_1_3_1_3_46_1","first-page":"35","article-title":"Measuring the maintenance of daily life activities using the Fuctional Living Index-Emesis (FLIE) in patients receiving\u00a0moderately emetogenic chemotherapy.","volume":"4","author":"Decker GM","year":"2006","unstructured":"Decker GM , DeMeyerES, KiskoDL: Measuring the maintenance of daily life activities using the Fuctional Living Index-Emesis (FLIE) in patients receiving\u00a0moderately emetogenic chemotherapy.J.\u00a0Support. Oncol.4, 35\u201341 (2006).","journal-title":"J.\u00a0Support. Oncol."},{"key":"e_1_3_1_3_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl137"},{"key":"e_1_3_1_3_48_1","first-page":"756","volume-title":"Proceedings of the American Society of Clinical Oncology.","author":"Cartmell AD","year":"2003","unstructured":"Cartmell AD , FergusonS, YanagiharaRet al.: Protection against chemotherapy-induced nausea and vomiting is maintained over multiple cycles of moderately or highly emetogenic chemotherapy by palonosetron, a potent 5-HT3 receptor antagonist. Proceedings of the American Society of Clinical Oncology. Chicago, IL, USA, 3041, 756 (2003) (Abstract)."},{"key":"e_1_3_1_3_49_1","article-title":"Palonosetron plus aprepitant and dexamethasone is a highly effective combination to prevent chemotherapy induced nausea and vomting after emetogenic chemotherapy.","author":"Grote T","year":"2006","unstructured":"Grote T , HajdenbergJ, CartmellADet al.: Palonosetron plus aprepitant and dexamethasone is a highly effective combination to prevent chemotherapy induced nausea and vomting after emetogenic chemotherapy.J.\u00a0Support Oncol. (2006) (In press).","journal-title":"J.\u00a0Support Oncol."},{"key":"e_1_3_1_3_50_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464070-00013"},{"key":"e_1_3_1_3_51_1","first-page":"369","article-title":"Palonosetron improves prevention of chemotherapy induced nausea and vomiting in elderly patients.","volume":"3","author":"Aapro MS","year":"2005","unstructured":"Aapro MS , MacciocchiA, GridelliC: Palonosetron improves prevention of chemotherapy induced nausea and vomiting in elderly patients.J.\u00a0Support. Oncol.3, 369\u2013374 (2005).","journal-title":"J.\u00a0Support. Oncol."},{"key":"e_1_3_1_3_52_1","article-title":"Infusion of palonosetron plus dexamethasone is effective and safe for the prevention of chemotherapy-induced nausea and vomiting.","author":"Hajdenberg J","year":"2006","unstructured":"Hajdenberg J , GroteT, YeeLet al.: Infusion of palonosetron plus dexamethasone is effective and safe for the prevention of chemotherapy-induced nausea and vomiting.J.\u00a0Support. Oncol. (2006) (In press).","journal-title":"J.\u00a0Support. Oncol."},{"key":"e_1_3_1_3_53_1","volume-title":"Proceedings of the American Society of Clinical Oncology","author":"Navari RM","year":"2006","unstructured":"Navari RM , EinhornLH, LoehrerPJet al.: A Phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and vomiting.Proceedings of the American Society of Clinical Oncology, Atlanta, GA USA (2006) (Abstract 8608)."},{"key":"e_1_3_1_3_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0755-6"},{"key":"e_1_3_1_3_55_1","first-page":"S494","volume-title":"Proceedings of the American Society of Clinical Oncology","author":"Brames MJ","year":"2006","unstructured":"Brames MJ , RothBJ, DreicerRet al.: Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer (Abstract).Proceedings of the American Society of Clinical Oncology, Atlanta, GA, USA, 24, S494 (2006) (Abstract 8607)."},{"key":"e_1_3_1_3_56_1","first-page":"413","article-title":"Post-marketing experience of palonosetron confirms a favorable benefit\/risk profile.","volume":"13","author":"Bissoli F","year":"2006","unstructured":"Bissoli F , McGiugganM, BertazzoliM: Post-marketing experience of palonosetron confirms a favorable benefit\/risk profile.Supp.\u00a0Care Cancer13, 413, (2006) (Abstract\u00a004\u2013017).","journal-title":"Supp.\u00a0Care Cancer"},{"key":"e_1_3_1_3_57_1","first-page":"510b","article-title":"Safety profile of palonosetron, a pharmacologically distinct\u00a05-HT3 receptor antagonist recently\u00a0approved for acute and delayed chemotherapy induced nausea.","volume":"102","author":"Hajdenberg JJ","year":"2003","unstructured":"Hajdenberg JJ : Safety profile of palonosetron, a pharmacologically distinct\u00a05-HT3 receptor antagonist recently\u00a0approved for acute and delayed chemotherapy induced nausea.Blood102, 510b (2003) (Abstract\u00a05770).","journal-title":"Blood"},{"key":"e_1_3_1_3_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-002-0427-3"},{"key":"e_1_3_1_4_2_1","unstructured":"MASCC antiemetic guidelines (2005) www.mascc.org"},{"key":"e_1_3_1_4_3_1","unstructured":"ASCO patient guide: Preventing nausea and vomiting caused by cancer treatment (2006) www.plwc.org"},{"key":"e_1_3_1_4_4_1","unstructured":"ASCO patient guide: preventing nausea and vomiting caused by cancer treatment (2006) www.plwc.org"},{"key":"e_1_3_1_4_5_1","unstructured":"Emend (aprepitant) capsules: prescribing information (2004) www.merck.com"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/14796694.2.5.591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:41:01Z","timestamp":1719124861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/14796694.2.5.591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,9]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,10,31]]}},"alternative-id":["10.2217\/14796694.2.5.591"],"URL":"https:\/\/doi.org\/10.2217\/14796694.2.5.591","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,9]]}}}